-
Arbutus Biopharma wins patent ruling against Moderna
-
Increasing unusual option volume: ABUS ECH AMTX ZSL RVMD XNET GFS CX UMC
-
Arbutus patent revoked by European Patent Office board
-
Arbutus Biopharma (ABUS) Misses Q3 EPS by 1c
-
Arbutus Biopharma (ABUS) Tops Q2 EPS by 5c
-
Arbutus Biopharma (ABUS) Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus
-
Arbutus Biopharma (ABUS) Misses Q1 EPS by 3c
-
Citizens JMP Reiterates Market Outperform Rating on Arbutus Biopharma (ABUS)
-
Genevant Sciences (ROIV) and Arbutus Biopharma (ABUS) Initiate International Patent Infringement Enforcement Actions Against Moderna
-
Arbutus Biopharma (ABUS) Appoints Lindsay Androski as CEO, Announces Board Changes
-
Arbutus Biopharma (ABUS) Provides 2025 Corporate and Financial Update
-
Arbutus Biopharma (ABUS) and Barinthus Bio (BRNS) Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
-
Arbutus Biopharma (ABUS) Misses Q2 EPS by 1c
-
Arbutus Biopharma (ABUS) Halted, News Pending
-
Increasing unusual option volume: ABUS TSEM BMBL IAU CMTL GTHX

